afamelanotide
Sign in to saveAlso known as α-NDP-MSH, [Nle4,dPhe7]α-MSH, NDP-MSH, MT-I, melanotan 1, melanotan I
Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria. It is a melanocortin 1 receptor (MC1 receptor) agonist and a synthetic peptide and analogue of α-melanocyte stimulating hormone. It is administered as subcutaneous implant.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 477364562
- Drug.image
- Melanotan.png
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Scenesse
- Drug.DailyMedID
- Afamelanotide
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- D02
- Drug.ATC_suffix
- BB02
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.elimination_half life
- 30 minutes
- Drug.index2_label
- as salt
- Drug.CAS_number
- 75921-69-6
via Wikipedia infobox
Research
117 papers- Afamelanotide.2012
- Afamelanotide in protoporphyria and other skin diseases: a review.Postepy dermatologii i alergologii · 2024
- PMID 402581052023
- Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.Expert review of clinical pharmacology · 2021
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications.Journal of drugs in dermatology : JDD · 2021
via PubMed
~6 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Chemistry
- History
- Society and culture
- Usage in general public
- References
Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria. It is a melanocortin 1 receptor (MC1 receptor) agonist and a synthetic peptide and analogue of α-melanocyte stimulating hormone. It is administered as subcutaneous implant.
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Excerpted from Wikipedia’s “afamelanotide” article, available under the CC BY-SA 4.0 licence.